Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 22, 2022
[ Wed, Jun 22nd 2022
] - WOPRAI
[ Wed, Jun 22nd 2022
] - WOPRAI
Tue, June 21, 2022
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
[ Tue, Jun 21st 2022
] - WOPRAI
David Macdonald Maintained (AMED) at Strong Buy with Decreased Target to $175 on, Jun 21st, 2022
David Macdonald of Truist Securities, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Decreased Target from $200 to $175 on, Jun 21st, 2022.
David has made no other calls on AMED in the last 4 months.
There are 6 other peers that have a rating on AMED. Out of the 6 peers that are also analyzing AMED, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Mok of "UBS" Upgraded from Strong Sell to Hold and Increased Target to $168 on, Tuesday, March 1st, 2022
These are the ratings of the 5 analyists that currently disagree with David
- A.J. Rice of "Credit Suisse" Maintained at Buy with Increased Target to $182 on, Friday, April 29th, 2022
- John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $180 on, Friday, April 29th, 2022
- Matt Borsch of "BMO Capital" Upgraded from Hold to Buy and Held Target at $190 on, Friday, February 25th, 2022
- Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $200 on, Friday, February 25th, 2022
- Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $175 on, Thursday, February 24th, 2022
